RACE ONCOLOGY LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.62 AUD | -1.82% |
|
+28.57% | +92.86% |
| 26/03 | Race Oncology Obtains Certificate of Analysis for RC220; Shares Up Almost 6% | MT |
| 18/03 | Race Oncology Limited(ASX:RAC) dropped from S&P/ASX All Ordinaries Index | CI |
Valuation
| Fiscal Period: June | 2024 | 2025 | 2026 |
|---|---|---|---|
| Capitalization 1 | 274.2 | - | - |
| Enterprise Value (EV) 1 | 264.9 | 240.7 | 252.7 |
| P/E ratio | -22.9 x | -20.4 x | -17.4 x |
| Yield | - | - | - |
| Capitalization / Revenue | - | - | - |
| EV / Revenue | - | - | - |
| EV / EBITDA | -22.8 x | -18.1 x | -16.4 x |
| EV / FCF | -23.2 x | -18.2 x | -16.4 x |
| FCF Yield | -4.3% | -5.48% | -6.09% |
| Price to Book | 16.5 x | - | 16.5 x |
| Nbr of stocks (in thousands) | 1,66,167 | - | - |
| Reference price 2 | 1.650 | 1.650 | 1.650 |
| Announcement Date | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2024 | 2025 | 2026 |
|---|---|---|---|
| Net sales 1 | - | - | - |
| EBITDA 1 | -11.6 | -13.3 | -15.4 |
| EBIT 1 | -11.9 | -13.6 | -15.7 |
| Operating Margin | - | - | - |
| Earnings before Tax (EBT) 1 | -11.7 | -13.5 | -15.7 |
| Net income 1 | -11.7 | -13.5 | -15.7 |
| Net margin | - | - | - |
| EPS 2 | -0.0720 | -0.0810 | -0.0950 |
| Free Cash Flow 1 | -11.4 | -13.2 | -15.4 |
| FCF margin | - | - | - |
| FCF Conversion (EBITDA) | - | - | - |
| FCF Conversion (Net income) | - | - | - |
| Dividend per Share | - | - | - |
| Announcement Date | - | - | - |
1AUD in Million2AUD
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2024 | 2025 | 2026 |
|---|---|---|---|
| Net Debt 1 | - | - | - |
| Net Cash position 1 | 9.3 | 33.5 | 21.5 |
| Leverage (Debt/EBITDA) | - | - | - |
| Free Cash Flow 1 | -11.4 | -13.2 | -15.4 |
| ROE (net income / shareholders' equity) | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - |
| Assets 1 | - | - | - |
| Book Value Per Share 2 | 0.1000 | - | 0.1000 |
| Cash Flow per Share 2 | -0.0700 | -0.0800 | -0.0900 |
| Capex 1 | - | - | - |
| Capex / Sales | - | - | - |
| Announcement Date | - | - | - |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +92.86% | 170M | |
| +5.33% | 111B | |
| +12.11% | 105B | |
| -12.56% | 22.34B | |
| -3.70% | 21.93B | |
| -6.03% | 18.59B | |
| -35.21% | 18.12B | |
| -10.86% | 16.96B | |
| +5.10% | 13.7B | |
| +37.57% | 12.45B |
- Stock Market
- Equities
- RAC Stock
- Financials Race Oncology Limited